全文获取类型
收费全文 | 1216篇 |
免费 | 81篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 82篇 |
妇产科学 | 11篇 |
基础医学 | 88篇 |
口腔科学 | 26篇 |
临床医学 | 84篇 |
内科学 | 203篇 |
皮肤病学 | 27篇 |
神经病学 | 29篇 |
特种医学 | 136篇 |
外科学 | 147篇 |
综合类 | 136篇 |
预防医学 | 82篇 |
眼科学 | 8篇 |
药学 | 128篇 |
中国医学 | 39篇 |
肿瘤学 | 85篇 |
出版年
2023年 | 10篇 |
2022年 | 17篇 |
2021年 | 29篇 |
2020年 | 28篇 |
2019年 | 21篇 |
2018年 | 22篇 |
2017年 | 14篇 |
2016年 | 23篇 |
2015年 | 31篇 |
2014年 | 47篇 |
2013年 | 54篇 |
2012年 | 69篇 |
2011年 | 61篇 |
2010年 | 76篇 |
2009年 | 70篇 |
2008年 | 34篇 |
2007年 | 40篇 |
2006年 | 46篇 |
2005年 | 44篇 |
2004年 | 22篇 |
2003年 | 28篇 |
2002年 | 18篇 |
2001年 | 16篇 |
2000年 | 12篇 |
1999年 | 23篇 |
1998年 | 45篇 |
1997年 | 60篇 |
1996年 | 52篇 |
1995年 | 40篇 |
1994年 | 32篇 |
1993年 | 31篇 |
1992年 | 10篇 |
1991年 | 6篇 |
1990年 | 13篇 |
1989年 | 25篇 |
1988年 | 19篇 |
1987年 | 18篇 |
1986年 | 17篇 |
1985年 | 10篇 |
1984年 | 12篇 |
1982年 | 9篇 |
1981年 | 9篇 |
1980年 | 11篇 |
1979年 | 3篇 |
1977年 | 6篇 |
1976年 | 6篇 |
1970年 | 3篇 |
1969年 | 3篇 |
1958年 | 4篇 |
1957年 | 2篇 |
排序方式: 共有1315条查询结果,搜索用时 15 毫秒
71.
维甲酸和联合应用神经营养因子对新生大鼠神经干细胞分化的影响 总被引:1,自引:0,他引:1
目的研究全反式维甲酸(ATRA)及联合应用神经营养因子(BDNF,GDNF)对体外培养的神经干细胞(NSCs)分化的影响。方法取新生SD大鼠的前脑室下带(SVZ)区,按NSCs的常规培养方法分离、培养。用免疫细胞化学法鉴定巢蛋白(nestin)、微管相关蛋白-2(MAP-2)、胶质原纤维酸性蛋白(GFAP)的表达,以此来观察ATRA、BDNF、GDNF单独或联合应用对次代神经球细胞分化的作用。结果原代及次代神经球均显示nestin阳性,并可分化为MAP-2阳性神经元样细胞及GFAP阳性胶质细胞样细胞。1μmol/LATRA可促进NSCs分化为MAP-2阳性细胞的比例达(29.14±5.00)%,显著高于对照组的(7.19±1.21)%,差异有高度统计学意义(P〈0.001)。ATRA联合应用10ng/ml的BDNF或GDNF,与单独使用ATRA比较,并不显著提高NSCs分化为MAP-2阳性细胞的比例。结论ATRA可促进神经干细胞向神经元方向分化,ATRA联合应用BDNF或GDNF无明显的协同作用。 相似文献
72.
目的通过构建以MDR1启动子为启动序列的双荧光素酶报告基因系统并进行活性分析,为MDR1基因表达的单靶点调控研究和逆转剂的筛选提供一种有效的方法。方法从HCT-8细胞中提取DNA并克隆含有MDR1基因启动子中Y—box序列。将该序列重组到萤光素酶报告基因载体pGL-3.Basic的启动区域中,从而构建报告基因载体pGL-MDR1。将pGL-MDR1和pRL-TK载体共转染到HCT-8和HCT-8/VCR细胞中。通过调节不同载体的比例来优化转染效率。利用MDRI基因激活剂(热诱导)和抑制剂(EGCG)等处理来分析其启动转录活性受外界因素的影响。结果通过直接测序法验证了pGL-MDR1含有MDR1基因启动子Y—box序列且没有出现碱基突变。在pGL-MDR1和pRL-TK的转染比例为5:5时,转染效率最高并具有最高的萤光素酶活性。通过MDR1基因激活处理后表现为时间依赖性地激活MDR1基因的表达,而MDR1基因抑制剂的作用则相反。结论MDR1启动子为启动序列的双荧光素酶报告基因系统建立成功。该系统不但可以用于研究活体生物发光成像和MDRI基因表达的机理,而且可用于单靶点的多药耐药抑制剂的筛选。 相似文献
73.
Relations between age, metabolic control, disease adjustment and psychological aspects in insulin-dependent diabetes mellitus 总被引:1,自引:0,他引:1
B Lernmark G Dahlqvist P Fransson B Hägglöf SA Ivarsson J Ludvigsson S Sjöblad G Thernlund 《Acta paediatrica (Oslo, Norway : 1992)》1996,85(7):818-824
The relations between age, metabolic control, disease adjustment, and psychological factors in boys and girls with recently diagnosed insulin-dependent diabetes mellitus (IDDM) were studied. Older girls had significant higher postremission glycosylated haemoglobin A (Hb Alc ) levels ( p = 0.008). Girls with more hospitalizations had a lower developmental level ( p = 0.05), and had significantly more problems in the behavioural rating ( p = 0.05). Boys with more hospitalizations had a more external locus of control ( p = 0.01), more difficulties with disease adjustment, more emotional problems, and were also clinically assessed as having more behavioural problems. Boys showing more difficulties in psychological adjustment to the disease also had higher postremission Hb A1c levels ( p = 0.02). Although Swedish children with IDDM of short disease duration do not differ from healthy children in important psychological aspects, older girls and a small group of problematic younger boys are at risk of developing metabolic imbalance after a short disease duration. 相似文献
74.
JW Gregory SA Greene RT Jung CM Scrimgeour MJ Rennie 《Archives of disease in childhood》1993,68(2):205-209
Fourteen children receiving one year of recombinant human growth hormone (rhGH) treatment underwent measurement of serial changes in body composition (measured by skinfold thickness, bioelectrical impedance, and H2(18)O dilution), resting energy expenditure (REE, estimated by ventilated hood indirect calorimetry), and total free living daily energy expenditure (TEE, measured by the doubly labelled water technique). Mean height velocity increased from 4.9 to 8.6 cm/year after six months of treatment. Fat free mass (FFM) increased more during the first six weeks (24.4 g/day) than from six to 26 weeks of treatment (6.8 g/day); fat mass decreased by 7.2 g/day and 1.1 g/day respectively. The six week increase in REE (kJ/day) was maintained after six months of treatment, though expressed per kilogram FFM (kJ/kgFFM/day), returned to pretreatment values by three months. Height velocity increases at six months correlated with six week changes in fat mass measured by skinfold thickness and REE, though use of this relationship to predict growth response in individuals is limited by the wide 95% prediction intervals. No significant changes in growth, body composition, or energy expenditure were observed between six and 12 months of treatment, in either patients who had initially responded well to treatment or those who were poor initial responders to treatment and who had their dose of rhGH doubled after six months. 相似文献
75.
76.
Recent reports have demonstrated that the HIV-1 transactivator protein,tat, induces apoptosis in T-lymphocyte cell lines, as well as in peripheral blood mononuclear cells, and stimulates a cascade
of events resulting in up-regulation of the potent immunosuppressive cytokine, transforming growth factor-β (TGF-β). In this
study we evaluated the ability of TGF-β to mediatetat induced apoptosis in T-lymphocyte cell lines. T-cells treated exogenously with either TGF-β1 or a combination of tat and
pan-specific TGF-β neutralizing antibodies showed little change in the amount of apoptosis. When treated with pan-specific
TGF-β neutralizing antibodies, Jurkat cells that stably expresstat protein (Jurkat-tat) showed only a modest decrease in apoptosis, while CEM-TART cells (CEM T-cells expressing both HIV-1tat andrev) demonstrated little change in the amount of apoptosis. In conclusion, we have demonstrated that TGF-β does not play a significant
role in mediatingtat induced T-cell apoptosis. 相似文献
77.
Commentary on acute renal failure in Asian region 总被引:1,自引:0,他引:1
78.
Implementation of the high-throughput microarray gene expression profiling technology towards "toxicogenomics" has advanced identification process for safer drugs in the century of 'omics' technology. Applying such technology, in fact, to identify mechanisms for cellular toxicity can provide a means to clarify safety liabilities early in the drug discovery and developments process. The underlying principle in gene therapy is primarily targeting a specific gene (e.g., for silencing). Hence, massive efforts have been devoted to validate the gene-based therapeutics, regardless of toxicogenomics potential of delivery systems. Of the gene delivery systems, viral and non-viral vectors, as two main paradigms, have so far been widely used for delivering of the genome-based therapeutics such as oligonucleotide, small interfering RNA and DNA. However, the use of viral vectors was narrowed due to the safety concerns. Non-viral vectors were utilized as safer alternatives for gene delivery in vitro and ex-vivo; though their success for in vivo gene therapy has been limited due to low efficiency and safety issues. Fundamental principle for gene therapy is to deliver gene-based therapeutics into target cells for specific gene targeting ideally with minimal cellular toxicity. Until now, few works have been conducted about geno-compatibility of delivery systems itself, including cationic lipid-based nanosystems. Inadvertent toxicogenomic impact of gene delivery systems (e.g., cationic lipids) may intrinsically affect the outcome of gene therapy, where often only a single desired genetic change is sought. Further, there exists a possibility that gene changes induced by the lipid delivery system itself could exacerbate, attenuate or even mask the desired effects of the gene-based therapeutics. This review will focus on toxicogenomics impact of the cationic lipid-based formulations for gene therapy. 相似文献
79.
80.